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Previewsimpinge on the Bcl6 locus where STAT5
can outcompete STAT3 on shared bind-
ing sites to repress Bcl6 transcription
(Figure 1). Rather than opening closed
doors in CD4+ T cell differentiation,
type I interferons’ interference in Tfh
deviates differentiation toward Th1 cells,
if STAT3-activating signals are missing.
Besides the known adjuvant effect of
type I interferon on non-T cells, the pre-
sent study demonstrates a crucial impor-
tance for balanced cytokine signals to
enable efficient Tfh cell differentiation in
vaccination strategies. At the same time,
it highlights the potential of STAT3 as a
target to treat autoimmune diseases that
involve Tfh cells.REFERENCES
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Immune activation as a result of the recognition of damage-associated molecular patterns needs to be
controlled. In this issue of Immunity, Neumann et al. (2014) demonstrates that Clec12a is a receptor for
dead cells through the recognition of uric acid crystals and contributes to the dampening of the responses.C-type lectin receptors (CLRs) are
pattern-recognition receptors (PRRs)
that recognize microbial pathogen-asso-
ciatedmolecular patterns (PAMPs), which
leads to the induction of host immune re-
sponses against many pathogens (Robin-
son et al., 2006). In addition to acting as
PRRs for PAMPs, some CLRs also func-
tion as receptors for damage-associated
molecular patterns (DAMPs), which are
exposed or released upon cell death by
noninfectious insults such as tissue injury,
ischemia, and infarction. For example,
Lox-1 and MGL-1 are CLRs known to
recognize dead cells and are likely to act
as phagocytic receptors for dead cells
(Robinson et al., 2006). Some CLRs
coupled with immunoreceptor tyrosine-
based activationmotif (ITAM) or hemITAM
(hemi-immunoreceptor tyrosine-based
activation motif), such as Mincle (Clec4e)
and DNGR-1 (Clec9a), have also beenshown to recognize dead cells (Sancho
et al., 2009; Yamasaki et al., 2008). These
CLRs sense nonhomeostatic cell death
and thereby induce inflammation or pro-
motion of antigen presentation. These
immune responses against ‘‘damaged
self’’ are thought to be beneficial to main-
tain homeostasis of the organisms. In
contrast, the ‘‘anti-self’’ responses should
be immediately terminated to prevent tis-
sue damage or autoimmunity caused by
prolonged halmful immune reaction
against self. To date, however, negative
regulatory CLRs for dead cells have never
been identified. Several CLRs possesses
immunoreceptor tyrosine-based inhibi-
tory motif (ITIM) within their own cyto-
plasmic tails. Upon receptor engagement,
tyrosine residues within ITIM are phos-
phorylated and thus provide docking sites
for cytosolic negative regulatory proteins
such as SHP-1, SHP-2, or SHIP. InT cells, ITIM-containing costimulatory
inhibitory receptors CTLA-4 and PD-1
play critical roles in terminating activatory
signals delivered through ITAM-contain-
ing T cell receptor (TCR) complexes in
order to prevent autoimmunity. Likewise,
it is possible that unknown inhibitory
CLR(s) contribute to the negative regula-
tion of immune responses against
damaged self.
Clec12a (also called myeloid inhibitory
C-type lectin-like receptor, MICL) was
originally described as an ITIM-containing
inhibitory CLR expressed by human gran-
ulocytes and monocytes (Marshall et al.,
2006). It was suggested that Clec12a rec-
ognizes some endogenous ligands as
soluble Clec12a could bind to single-cell
suspensions isolated from various murine
tissues (Pyz et al., 2008). In this issue of
Immunity, Neumann et al. (2014) identified
Clec12a as an inhibitory CLR for dead0, March 20, 2014 ª2014 Elsevier Inc. 309
Figure 1. Schematic Representation of the Negative Regulation of Immune Responses
against Damaged Self by Clec12a
Excessive or deregulated cell death results in the release of DAMPs. Among them, uric acid forms MSU
crystal by contacting extracellular sodium ions. MSU can be opsonized with antibodies and thus binds
to cell surface Fc receptors coupled with ITAM-containing FcRg chain. MSU crystals activate myeoloid
cells through CD11b and/or FcgRIII and membrane lipid in a Syk-dependent manner, which leads to
ROS production. Clec12a is likely to inhibit Syk activation presumably through recruiting PTPase to the
phosphorylated ITIM. MSU crystal also induces IL-1b production via inflammasome. This inflamasome-
dependent pathway appears to be resistant to Clec12a-mediated negative regulation. The effect of
Clec12a on other receptors for DAMPs, such as TLRs and CLRs, remains unclear.
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Previewscells. The authors found that mouse and
human Clec12a recognizes dead cells
derived from 293T cells or thymocytes
by using Clec12a-immunoglobulin (Ig)
fusion protein and reporter cells express-
ing Clec12a-CD3z chimera. Clec12a also
recognized dead cells from meshed
murine organs. To further characterize
the ligand components, the authors
treated killed kidney cells with DNase,
RNase, trypsin, and inhibitor of uric acid
synthesis. Among these, only uric acid in-
hibitor could eliminate Clec12a-Ig binding
to dead cells. Uric acid is soluble within
healthy cells, but when it is contact with
extracellular sodium ions upon cell death,
uric acid forms monosodium urate (MSU)
crystal. Neumann et al. demonstrated that
MSU is a direct ligand for Clec12a.
Deposition of MSU crystal causes
a common inflammatory arthritis called
gout. MSU is a DAMP associated
with cell death (Shi et al., 2003). How-
ever, the molecular mechanism underly-
ing the ‘‘crystal-induced’’ inflammatory
responses has remained elusive. It has
been thought that MSU is opsonized
with antibodies, which might trigger Fc310 Immunity 40, March 20, 2014 ª2014 Elsereceptors coupled with FcRg chain (Shi
et al., 2010). In addition, inflammatory
MSU induces Syk activation through the
engagement of FcgRIII and CD11b in
neutrophils (Barabe´ et al., 1998). It is
also proposed that direct membrane
binding of MSU results in cell-surface lipid
sorting and Syk activation in an ITAM-in-
dependent fasion (Shi et al., 2010). In
contrast, Martinon et al. reported that
MSU crystals activate NRLP3 inflamma-
some, followed by the secretion of active
(mature) interleukin-1b (IL-1b) through
caspase-1 activation (Martinon et al.,
2006). To maintain tissue homestasis
by preventing excessive ‘‘detrimental’’
inflammation, these immune responses
against MSU need to be strictly regulated.
To gain insight into the physiological
relevance of this finding, Neumann
et al. generated Clec12a-deficient mice
and investigated neutrophil activation in
response to MSU. As previously reported,
MSU induced reactive oxygen species
(ROS) production in a Syk-dependent
manner, and it was substantially
increased in the absence of Clec12a.
Thus, Clec12a is likely to downmodulatevier Inc.MSU response through the inhibition of
Syk activity, although this was not ad-
dressed in this study. This phenomenon
was also confirmed by in vivo experi-
ments in which MSU crystal was injected
into the peritoneum of mice. MSU-
induced neutrophil infiltration to perito-
neal cavity was augmented in Clec12a–/–
mice. In contrast, ROS production
induced by irrelevant Dectin-1 ligand
was not enhanced in Clec12a–/– mice,
implying that coengagement with acti-
vating receptor might be required for
Clec12a to exert its inhibitory effects. It
would be intriguing to test whether anti-
body-mediated crosslinking of Clec12a
could suppress activation of immune cells
induced by PRRs for other DAMPs.
Finally, Neumann et al. investigated
noninfectious inflammation induced by
dead cells in vivo. Infiltration of neutrophil
in response to dead cells was significantly
enhanced in the absence of Clec12a.
Thus, Clec12a appears to be an inhibitory
CLR that senses dead cells to control
sterile inflammation (Figure 1).
Several interesting questions remain to
be solved. Currently, it is unclear how
Clec12a can recognize MSU. The nature
of the MSU crystals such as ‘‘rugged-
ness’’ has been thought to be linked to
the different inflammatory potential (Shi
et al., 2010). Does Clec12a discriminate
different ‘‘shape’’ or ‘‘size’’ of the crys-
tals? Further understanding of the binding
mode will be achieved by the structural
analyses of the crystallized Clec12a-
MSU complex. Alternatively, it is con-
ceivable that other components such as
opsonizing proteins, carbohydrates,
lipids, or nucleic acids might modulate
the interaction of MSU with Clec12a. In
addition, because Clec12a possesses
ITIM within the cytoplasmic tail, some
PTPases are likely tomediate the negative
regulatory role of Clec12a. More detailed
studies will clarify the cytosolic inhibi-
tory signaling pathways underlying the
negative regulation.
It is still an open question whether MSU
is the sole ligand for Clec12a. Other
endogenous ligand(s) derived from dead
cells might also contribute to attenuate
sterile inflammation through the use of
Clec12a. In contrast, it is reported that
MSU is recognized by the inflammasome,
which leads to the production of proin-
flammatory cytokine IL-1b. Given that
this pathway appeared to be resistant to
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PreviewsClec12a (Neumann et al., 2014), other
intracellular sensor(s) for MSU might be
operating in the negative regulation of
inflammasome-caspase-1 axis. MSU is
characterized as an endogenous adjuvant
that promotes acquired immune re-
sponses (Shi et al., 2003). Because
Clec12a is also expressed in dendritic
cells, it would be valuable to examine
whether Clec12a can inhibit T cell-medi-
ated immunity by regulating antigen-
presenting cells.
These findings shed light on ITIM-con-
taining CLRs as important negative regu-
lators that potentially dampen immune
responses against DAMPs. The develop-
ment of selective agonist for Clec12a is
of interest in the treatment of a variety ofinflammatory diseases associated with
high systemic uric acid levels, such as
arthritis, atherosclerosis, cardiovascular
diseases, and type 2 diabetes.REFERENCES
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In this issue of Immunity, Kim et al. (2014) propose that CD103+ DCs in mouse lung selectively generate
effector CD8+ T cells by binding the alarmin HMGB1 via CD24 and presenting it to RAGE+ T cells.Whether the same dendritic cell (DC) can
prime all kinds of T cells or whether indi-
vidual T cell populations require antigen
to be presented by separate populations
of DCs has long been an issue in immu-
nology. Addressing these questions is
important not just for understanding the
basic tenets of immune function, but
also for identifying which DC might be
useful to target in designing vaccines or
tailoring immunotherapy.
In this issue of Immunity, Kim et al.
(2014) show that separate DC subsets
in the influenza A virus (IAV)-infected lung
may play distinct roles in driving local
effector ormemoryCD8+Tcell responses.
Whereas CD103+CD11b DCs generate
short-lived CD8+ effector T cells that
home to the lung and confer protective
immunity, CD103CD11b+ DCs drive the
generation of ‘‘central memory’’ CD8+
T cells that reside in secondary lymphoid
organs for long periods after infection.The CD103+ DCs that drive effector CD8+
T cell differentiation express very high
amounts of CD24; blockade and overex-
pression of CD24 show that the amount
of CD24 controls whether effector or
memory CD8+ T cells are generated by
the same virus challenge. It is proposed
that CD24 acts by allowing CD103+ DCs
to decorate their surfacewith highmobility
group box 1 (HMGB1) protein, a histone-
related protein that acts as a damage-
associated molecular pattern (DAMP)
molecule when released from dying cells
in the lung (Ullah et al., 2014) and whose
receptor, RAGE (receptor for advanced
glycation endproducts), can act as a cos-
timulatory signal in T cells (Moser et al.,
2007). Kim et al. (2014) then demonstrate
that blocking the interaction between
CD24, HMGB1, and RAGE markedly in-
hibits priming of CD8+ T cells in vivo and
in vitro. The authors conclude thatCD103+
DCs can thus provide the strong signalneeded to generate effector CD8+ T cells
(Figure 1). It is known that efficient T cell
priming and high amounts of IL-2 produc-
tion favor the differentiation of short-lived
effector versus long-lived memory CD8+
T cells (Kalia et al., 2010). This has usually
been assumed to reflect differences in
the TCR-pMHC interaction. The work of
Kim et al. (2014) now suggests that
such decisions are not controlled simply
via the TCR, but involve additional non-
antigen-specific costimulatory processes
such as the CD24-HMGB1-RAGE axis.
The current work may also help explain
apparent contradictions in the literature
about how CD103+ and CD11b+ DCs
may divide their labor in CD8+ T cell
responses in the lung. Although a con-
sensus has subsequently arisen that
migratory CD103+ DCs play the dominant
role in priming CD8+ T cell responses in
the MedLN, a role for migratory CD11b+
DCs has also long been suspected0, March 20, 2014 ª2014 Elsevier Inc. 311
